Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



'No Evidence of Disease Activity' in MS: What Is NEDA, Anyway?

Image Credit: Thinkstock

Since the first disease-modifying therapy (DMT) for MS was approved by the FDA in 1993, medications for MS have been developed to slow down the disease. Many have been shown in clinical studies to reduce the frequency of relapse and slow the accumulation of permanent disability.

As early as 2010, MS researchers began to suggest that rather than simply slowing down the disease, a clinical goal of therapy could be “freedom from disease activity.” The idea is that measuring the number of people with MS who can achieve freedom from disease activity could become a better gauge to determine therapeutic effectiveness. The concept is now referred to as “no evidence of disease activity,” or NEDA, for short.

What is NEDA?

While the definition of NEDA is evolving, “no evidence of disease activity” means exactly what is sounds like. A person with MS would show no signs of active disease — but this doesn’t mean that old symptoms or disability would disappear. For NEDA to occur, three conditions need to be met, the combination of which is sometimes called NEDA3.

  • No clinical relapses or exacerbations
  • No Gd-enhancing (active) lesions and/or no new or newly-enlarging T2 lesions
  • No change in the neurological exam or confirmed disability progression

Note that these measures are focused primarily on inflammatory disease activity and do not readily capture other disease consequences, such as neurodegeneration. Researchers have suggested the addition of a fourth measure — brain volume loss— to provide a more comprehensive view of disease activity and progression. This new criteria is called NEDA4.

Why measure brain atrophy?

Brain volume loss (BVL), also called brain atrophy, correlates with disability progression and cognitive decline in people with MS. It can result from lesions in the brain's grey matter and damage in normal-appearing white and grey matter. Studies have determined that an annual BVL rate of 0.4 percent or more can distinguish between people with MS and healthy individuals who generally experience BVL rates between 0.1 and 0.3 percent each year. To begin to test the theory that NEDA4 provides a more comprehensive assessment of disease activity and progression, researchers have applied the criteria to clinical trial data of different MS therapies (such as fingolimod, peginterferon beta-1a, or other oral therapies). Results suggest that the new four-parameter measure has the potential to capture the impact of therapy on both inflammation and neurodegeneration.

Using NEDA to make treatment decisions

Much of the discussion surrounding NEDA (3 or 4) is among MS researchers and scientists. The concept has not been routinely applied to clinical practice. However, researchers suggest that brain atrophy and cognitive function should be routinely measured and used by neurologists to help patients make more informed treatment choices. The sensitivity of NEDA to detect treatment response and predict future disability may be helpful in deciding when to switch treatments for patients who do not respond to therapy.

NEDA is difficult to maintain over time, but sustained NEDA can predict future lack of disability progression. In a 7-year study, a total of 99 of 215 patients (46 percent) achieved NEDA at year one, but only 7.9 percent maintained NEDA status through year seven. Demonstrating the prognostic power of NEDA, researchers noted that 78.3 percent of patients who still had NEDA status at year two experienced no disability progression by year seven.

This would suggest that using NEDA to make treatment decisions could be helpful in avoiding disability progression. However, there are researchers who point out that NEDA may not be a valid long-term measure because it is not easy to determine whether a patient is “doing well simply because they are not doing badly or because they are taking a particular medication.”

In other words, it might be that NEDA status is more indicative of benign MS than treatment effectiveness.

Disease activity is complex and often hidden

Looking for NEDA, or rather its converse, EDA (evidence of disease activity), demonstrates how MS can be active without causing obvious outward signs. Patients can become confused or frustrated when symptoms, relapses, or disability progression are not represented by changes on MRI scans.

Story Source: The above story is based on materials provided by HEALTHCENTRAL
Note: Materials may be edited for content and length

Go to Newer News Go to Older News